Drug Design, Development and Therapy (Feb 2023)
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
Abstract
Kamaneh Montazeri,1 Vikram Pattanayak,2 Ryan J Sullivan1 1Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA; 2Department of Pathology, Massachusetts General Hospital, Boston, MA, USACorrespondence: Ryan J Sullivan, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, USA, Tel +1 617-724-4000, Email [email protected]: Uveal melanoma (UM) is a rare type of melanoma with distinct features from cutaneous melanoma, low response rates to immune checkpoint inhibition, and poor survival rates. Tebentafusp, a bispecific antibody engaging T cells with gp 100 on HLA-A*02:01, was recently approved by the FDA as the first drug of its class and the first treatment approved by the FDA to treat UM. In this review, we summarize the preclinical and clinical data on tebentafusp for UM. We additionally discuss patient selection and the relevant challenges. For the literature search, PubMed search and relevant articles presented at international conferences were used.Keywords: metastatic uveal melanoma, T cell engaging agents, T cell receptor, gp 100, HLA-A*02:01
